Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK – A16037)

BACKGROUND: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor abiraterone irreversibly inhibits androgen biosynthesis. The Cancer of the Ovary Ab...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ther Adv Med Oncol
Päätekijät: Banerjee, Susana, Tovey, Holly, Bowen, Rebecca, Folkerd, Elizabeth, Kilburn, Lucy, McLachlan, Jennifer, Hall, Marcia, Tunariu, Nina, Attygalle, Ayoma, Lima, Joao Paulo Da Silveira Nogueira, Perry, Sophie, Chatfield, Peter, Hills, Margaret, Kaye, Stan, Attard, Gert, Dowsett, Mitch, Bliss, Judith M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: SAGE Publications 2020
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8013695/
https://ncbi.nlm.nih.gov/pubmed/33854564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920975352
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia